Stockscreener 앱 받기
6.66
5.05%
0.32
시간 외 거래:
6.79
0.13
+1.95%
전일 마감가:
$6.34
열려 있는:
$6.63
하루 거래량:
94,392
Relative Volume:
1.21
시가총액:
$154.80M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+10.63%
1개월 성능:
-9.39%
6개월 성능:
+1.06%
1년 성능:
-19.57%
1일 변동 폭
$6.42
$6.83
1주일 범위
$5.7501
$6.83
52주 변동 폭
$5.47
$11.99
Actuate Therapeutics Inc Stock (ACTU) Company Profile
명칭
Actuate Therapeutics Inc
전화
847-986-4190
주소
1751 RIVER RUN, FORT WORTH
ACTU을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
6.66 | 147.36M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-26 | 개시 | B. Riley Securities | Buy |
| 2025-04-22 | 개시 | Craig Hallum | Buy |
| 2025-03-17 | 개시 | H.C. Wainwright | Buy |
Actuate Therapeutics Inc 주식(ACTU)의 최신 뉴스
Actuate Therapeutics stock gets Buy rating after positive Phase 1 results - Investing.com Nigeria
Actuate Therapeutics stock rises on positive pediatric cancer trial data By Investing.com - Investing.com Australia
Actuate Therapeutics stock rises on positive pediatric cancer trial data - Investing.com
Actuate Therapeutics Announces Positive Patient Outcomes - GlobeNewswire
Analyst Downgrade: Is Actuate Therapeutics Inc stock supported by innovation pipelineTrade Performance Summary & Daily Profit Focused Stock Screening - moha.gov.vn
Actuate Therapeutics (NASDAQ:ACTU) Trading 2.7% Higher – Here’s What Happened - Defense World
Actuate Therapeutics (NASDAQ:ACTU) Trading 2.7% HigherHere's What Happened - MarketBeat
Can Actuate Therapeutics' Elraglusib Overcome The Hurdles Of GSK-3ß Inhibition? - RTTNews
Actuate Therapeutics, Inc. (ACTU) upgraded to buy: What does it mean for the stock? - MSN
Actuate Therapeutics, Inc. (ACTU) Upgraded to Buy: What Does It Mean for the Stock? - sharewise.com
Can Actuate Therapeutics Inc stock maintain growth trajectoryJuly 2025 Drop Watch & Consistent Income Trade Ideas - moha.gov.vn
Why Actuate Therapeutics Inc. stock remains on buy lists2025 Top Decliners & Real-Time Price Movement Reports - Улправда
What risks investors should watch in Actuate Therapeutics Inc. stockJuly 2025 Trends & Growth Focused Stock Pick Reports - Улправда
Why Actuate Therapeutics Inc. stock is recommended by analystsWeekly Gains Summary & Long-Term Safe Investment Ideas - Улправда
How Actuate Therapeutics Inc. stock reacts to oil pricesJuly 2025 WrapUp & Daily Profit Focused Screening - DonanımHaber
How sustainable is Actuate Therapeutics Inc. stock dividend payoutBull Run & AI Forecasted Entry/Exit Points - DonanımHaber
Can Actuate Therapeutics Inc. stock maintain growth trajectory2025 Technical Patterns & Verified Technical Trade Signals - DonanımHaber
What Wall Street predicts for Actuate Therapeutics Inc. stock priceJuly 2025 Earnings & Low Volatility Stock Recommendations - Улправда
Actuate to present phase 2 pancreatic cancer study data at ASCO GI By Investing.com - Investing.com South Africa
Fed Meeting: Is Actuate Therapeutics Inc. stock a buy for dividend growthStop Loss & Free Community Consensus Stock Picks - Улправда
Is Actuate Therapeutics Inc. stock a buy for dividend growthQuarterly Trade Review & Consistent Income Trade Recommendations - Улправда
Actuate to present phase 2 pancreatic cancer study data at ASCO GI - Investing.com Nigeria
Actuate Therapeutics Announces Presentation of Phase 2 Study Data on Elraglusib in Metastatic Pancreatic Cancer at ASCO GI Cancers Symposium 2026 - Quiver Quantitative
Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026 - The Manila Times
Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer - GlobeNewswire
Actuate reports promising results for elraglusib in salivary cancer By Investing.com - Investing.com Australia
Actuate reports promising results for elraglusib in salivary cancer - Investing.com
Actuate Therapeutics Announces Promising Phase II Study Results for Elraglusib in Advanced Salivary Gland Cancer - Quiver Quantitative
Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma - GlobeNewswire
Actuate Therapeutics Reports Positive Phase II Data In Salivary Gland Cancers - Nasdaq
Certain Options of Actuate Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2025. - marketscreener.com
Voss Capital LP Purchases 143,759 Shares of Actuate Therapeutics, Inc. $ACTU - MarketBeat
Actuate Therapeutics, Inc. (ACTU)’s Elraglusib Elraglusib Trial Hits Key Goals in Pancreatic Cancer - MSN
Published on: 2025-12-07 08:30:16 - BỘ NỘI VỤ
Will Actuate Therapeutics Inc. stock see PE expansionInsider Selling & Daily Chart Pattern Signal Reports - Newser
Why Actuate Therapeutics Inc. stock is a must watch in 2025Forecast Cut & AI Based Buy and Sell Signals - Newser
Actuate Therapeutics enters $100 million at-the-market sales agreement - Investing.com
Actuate Therapeutics Signs $100M Sales Agreement - TipRanks
Actuate Therapeutics Inc enters at the market issuance sales agreement with B. Riley and Craig-HallumSEC filing - marketscreener.com
How Much Upside is Left in Actuate Therapeutics, Inc. (ACTU)? Wall Street Analysts Think 214.06% - Zacks Investment Research
Actuate Therapeutics, Inc.'s (NASDAQ:ACTU) market cap surged US$24m last week, private equity firms who have a lot riding on the company were rewarded - simplywall.st
BIOS Capital Management LP Buys 71,428 Shares of Actuate Therapeutics, Inc. $ACTU - Defense World
What analysts say about Actuate Therapeutics Inc stockTrade Execution Strategies & Daily Tips From Top Market Analysts - earlytimes.in
Will Upside Catalysts Materialize for Prime Industries Limited in YEARHigh Frequency Trading Trends & Free Unlock Rapid Growth Potential - earlytimes.in
HC Wainwright Has Bullish Estimate for ACTU FY2025 Earnings - Defense World
Why Actuate Therapeutics Inc. stock is in analyst buy zoneEarnings Trend Report & Verified Entry Point Signals - newser.com
Actuate Therapeutics (NASDAQ:ACTU) Given "Buy" Rating at HC Wainwright - MarketBeat
Actuate Therapeutics: Strategic Advancements and Financial Outlook Drive Buy Rating - TipRanks
HC Wainwright & Co. Reiterates Actuate Therapeutics (ACTU) Buy Recommendation - Nasdaq
How Actuate Therapeutics Inc. stock compares to market leadersEarnings Overview Report & Expert Approved Momentum Ideas - newser.com
Using R and stats models for Actuate Therapeutics Inc. forecastingRate Hike & Fast Gaining Stock Reports - newser.com
Actuate Therapeutics Inc (ACTU) 재무 분석
Actuate Therapeutics Inc (ACTU)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
2.52%
0.07%
자본화:
|
볼륨(24시간):